Bill
S 6937
Bill S 6937 limits substituting traditional opioids with abuse-deterrent versions, aiming to enhance patient safety and reduce opioid misuse in pain management.
Title: Limits the substitution of abuse-deterrent analgesic opioid drug products for analgesic opioids lacking such technology
Bill Number: S 6937
Introduced On: March 27, 2025
Current Status: Referred to Insurance
Classification: Bill
Bill S 6937 aims to address the ongoing opioid crisis by regulating the substitution of opioid medications. Specifically, it seeks to limit the substitution of traditional analgesic opioids with abuse-deterrent formulations. The intent is to promote the use of safer opioid alternatives that are designed to reduce the potential for misuse and abuse.
Substitution Limitations: The bill proposes that healthcare providers and pharmacists may not substitute an abuse-deterrent analgesic opioid with a non-abuse-deterrent opioid unless certain criteria are met. This is intended to ensure that patients who require pain management are prescribed medications that are less likely to be misused.
Criteria for Substitution: The bill outlines specific conditions under which substitution may occur, potentially including patient-specific factors or lack of availability of the abuse-deterrent formulation.
Insurance Implications: The bill is referred to the Insurance committee, indicating that it may involve changes to insurance coverage policies regarding opioid prescriptions. This could affect how insurers reimburse for abuse-deterrent versus non-abuse-deterrent opioids.
Patients: Individuals requiring pain management who are prescribed opioids will be directly impacted, as the bill aims to provide them with safer medication options.
Healthcare Providers: Physicians and pharmacists will need to adapt their prescribing and dispensing practices in accordance with the new regulations set forth by the bill.
Insurance Companies: Insurers may need to revise their policies and reimbursement structures to comply with the new substitution rules.
Legislative Process: The bill was introduced on March 27, 2025, and has been referred to the Insurance committee for further consideration. The timeline for further legislative action is not specified but will depend on the committee's review and subsequent votes.
Related Legislation: This bill is part of a broader legislative context, with several related bills from prior sessions (S 6962, S 7009, S 3272, S 6180, S 4754) and a companion bill (A 7920) that may influence or complement its provisions.
Bill S 6937 represents a significant step towards enhancing the safety of opioid prescriptions by limiting the substitution of abuse-deterrent formulations. By focusing on reducing the potential for opioid misuse, the bill aims to protect patients and promote responsible prescribing practices in the healthcare system. The outcome of this bill will depend on its progress through the legislative process and the responses from stakeholders in the healthcare and insurance sectors.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
